You are here
GLYCOMIRA, LLC
UEI: JZG1CTLKTUP3
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis
Amount: $304,921.00PROJECT SUMMARYThe goal of this proposal is to optimize and clinically validate a new diagnostic test for eosinophilic chronic rhinosinusitis (eCRS) at the point-of-care, improving the efficiency, val ...
STTRPhase I2023Department of Health and Human Services National Institutes of Health -
Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis
Amount: $2,826,053.00Project Summary/Abstract Oral mucositis is a devastatingly painful inflammatory disease that frequently develops during cancer therapy and affects half a million Americans. The accompanying pain is so ...
SBIRPhase II2021Department of Health and Human Services National Institutes of Health -
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis
Amount: $1,975,971.00PROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 12% of the population and substantially diminishing the quality of life and ...
SBIRPhase II2021Department of Health and Human Services National Institutes of Health -
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis
Amount: $2,406,859.00PROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 16% of the population and substantially diminishing the quality of life and ...
SBIRPhase II2018Department of Health and Human Services National Institutes of Health -
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis
Amount: $297,614.00PROJECT SUMMARY This proposal aims to develop a therapeutic capable of preventing and treating the severe sinus inflammation associated with chronic rhinosinusitis CRS CRS is a debilitating inflamm ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
Glycosaminoglycans to Treat and Prevent Radiation Induced Oral Mucositis
Amount: $746,312.00ABSTRACT Oral mucositis is a devastatingly painful inflammatory disease that frequently develops during cancer therapy and affects half a million people in the US The accompanying pain is so severe ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis
Amount: $199,997.00DESCRIPTION (provided by applicant): GlycoMira Therapeutics has developed safe and effective anti-inflammatory glycosaminoglycan derivatives and proposes to test the feasibility of using its lead com ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis
Amount: $1,507,000.00DESCRIPTION provided by applicant Chronic gingival inflammation of the soft tissue surrounding the tooth afflicts over half of all American adults In the most severely affected progression of th ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Novel Glycosaminoglycan Ethers for Prevention of Metastasis
Amount: $210,000.00DESCRIPTION (provided by applicant): Heparin and its derivatives block P- and L-selectin mediated metastatic spread of cancer in animal models, and they potently inhibit the matrix degrading enzyme he ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis
Amount: $210,000.00DESCRIPTION (provided by applicant): Chronic gingival inflammation afflicts over half of all American adults and can progress to periodontal disease, eventually resulting in tooth loss. Periodontitis ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health